Table 2.
Cell cycle analysis of KLE cells treated with probe prodrugs DB289 and DB844.
| Treatment | Sub-G1 | G0/G1 | S | G2/M | >4N | ||
|---|---|---|---|---|---|---|---|
| Prodrug | α-NFb | ||||||
| Untreated | − | 5.2 ± 1.0a | 36.8 ± 3.5 | 13.6 ± 0.1 | 44.7 ± 0.5 | 3.4 ± 0.7 | |
| DB289 | 10 μM | − | 5.1 ± 1.4 | 40.0 ± 1.7 | 5.3 ± 1.1*** | 45.0 ± 5.2 | 1.7 ± 0.6 |
| 100 μM | − | 4.5 ± 0.7 | 43.2 ± 0.8* | 8.3 ± 1.0*** | 39.5 ± 0.2 | 4.5 ± 1.3 | |
| DB844 | 10 μM | − | 4.6 ± 0.8 | 38.7 ± 2.1 | 8.0 ± 1.4*** | 47.3 ± 0.5 | 6.3 ± 1.9 |
| 100 μM | − | 5.3 ± 1.5 | 43.9 ± 1.2** | 6.6 ± 1.1*** | 40.6 ± 1.3 | 3.7 ± 0.9 | |
| Untreated | + | 5.2 ± 1.6 | 42.0 ± 4.0 | 9.0 ± 2.5 | 38.8 ± 5.8 | 3.9 ± 1.7 | |
| DB289 | 10 μM | + | 5.4 ± 0.0 | 39.5 ± 0.6 | 9.8 ± 1.4 | 39.3 ± 2.9 | 5.3 ± 1.0 |
| 100 μM | + | 4.7 ± 1.0 | 43.2 ± 3.4 | 6.1 ± 1.1 | 42.4 ± 2.6 | 3.6 ± 0.4 | |
| DB844 | 10 μM | + | 4.1 ± 1.1 | 41.1 ± 1.5 | 7.9 ± 1.5 | 40.7 ± 2.9 | 4.9 ± 0.9 |
| 100 μM | + | 4.3 ± 0.9 | 43.3 ± 0.4 | 5.6 ± 0.7 | 41.8 ± 1.1 | 3.4 ± 0.6 | |
a
Values denote % of cells in each phase of cell cycle and represent means ± standard deviations of triplicate determinations.
b
α-NF concentration was 10 μM.
*
P < 0.05,
**
P < 0.01,
***
P < 0.001,
compared to untreated cells of the corresponding α-NF treatment group (one-way ANOVA with Dunnett post test).